Last Updated: August 25, 2026

CLINICAL TRIALS PROFILE FOR PF-06826647

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for PF-06826647

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03210961 ↗	A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis	Completed	Pfizer	Phase 1	This first in human study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-06826647 in healthy subjects and subjects with plaque psoriasis.
NCT03895372 ↗	A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis	Completed	Pfizer	Phase 2	This multicenter study is being conducted to provide additional PF-06826647 safety and tolerability data, and to further explore the clinical efficacy of PF-06826647 in the treatment of moderate to severe plaque psoriasis. Additionally, the study is intended to enable selection of oral dose and dosing regimen for the future clinical development of PF-06826647.
NCT04092452 ↗	A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa	Active, not recruiting	Pfizer	Phase 2	This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks. This includes an up to 6-week Screening Period, a 16 week Dosing Period and a 4 week Follow up Period.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for PF-06826647

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Healthy	2
Acne Inversa	1
Plaque Psoriasis	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Psoriasis	2
Hidradenitis	1
Ulcer	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for PF-06826647

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	41
Canada	6
Poland	4
Australia	4
Japan	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Florida	4
California	4
Georgia	3
Texas	3
Oklahoma	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for PF-06826647

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	3
Phase 1	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	4
Active, not recruiting	1
Withdrawn	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PF-06826647

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Pfizer	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.